scispace - formally typeset
M

Matthew Blades

Researcher at University of Leicester

Publications -  11
Citations -  786

Matthew Blades is an academic researcher from University of Leicester. The author has contributed to research in topics: Locus (genetics) & Genome-wide association study. The author has an hindex of 8, co-authored 11 publications receiving 664 citations. Previous affiliations of Matthew Blades include Medical Research Council.

Papers
More filters
Journal ArticleDOI

The impact of low-frequency and rare variants on lipid levels.

Ida Surakka, +98 more
- 01 Jun 2015 - 
TL;DR: Using a genome-wide screen of 9.6 million genetic variants achieved through 1000 Genomes Project imputation in 62,166 samples, association to lipid traits in 93 loci is identified, including 79 previously identified loci with new lead SNPs and 10 new loci, including 15 locu with a low-frequency lead SNP and 10 loco with a missense lead SNP.
Journal ArticleDOI

Discovery and Fine-Mapping of Glycaemic and Obesity-Related Trait Loci Using High-Density Imputation.

Momoko Horikoshi, +104 more
- 01 Jul 2015 - 
TL;DR: This study demonstrates that 1000G imputation and genetic fine-mapping of common and low-frequency variant association signals at GWAS loci, integrated with genomic annotation in relevant tissues, can provide insight into the functional and regulatory mechanisms through which their effects on glycaemic and obesity-related traits are mediated.
Journal ArticleDOI

Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo.

TL;DR: It is shown that Histone Deacetylase 1 and 2 (HDAC1/2), the catalytic core of numerous co-repressor complexes, are important histone decrotonylase enzymes.
Journal ArticleDOI

Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes

TL;DR: It is shown that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins, and arginase antagonizes chemotherapeutic drugs oxaliplatin and 5-fluorouracil (5-FU), whereas ADI-PEG20 synergizes with oxali platin in ASS1-negative cell lines and appears to interact with 5- fluorourACil independently of ASS1 status.